Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
A Chemical & Engineering News feature published in June 2026, drawing on data from the CAS Content Collection, documented the cyclic-peptide patenting surge over 2020 to April 2026. Chinese universities are the top filers globally on cyclic peptides. Outside China, US universities lead. Among corporates, Bicycle Therapeutics and Bristol Myers Squibb were called out for sustained patent activity covering cancer, infectious, inflammatory, and autoimmune disease indications. The article frames cyclic peptides as bridging the small-molecule and biologic divide: enhanced conformational rigidity, elimination of unstable terminal residues, and improved metabolic stability are the structural advantages that allow some cyclic peptides to be dosed orally. Merck's enlicitide decanoate (MK-0616, oral PCSK9 macrocyclic peptide for hyperlipidemia) was cited as the proof point for oral-pill cyclic-peptide drug development; an enlicitide NDA submission was underway as of mid-2026. The broader market backdrop: macrocyclic and stapled peptides are projected to grow from $1.22 billion in 2024 to $4.76 billion by 2030 at a 21.44% CAGR, driven mostly by oncology pipelines and the macrocyclic deal flow that includes the Unnatural Products-Novartis $1.7-1.8B cardiovascular pact (February 2026), Biogen-Dayra $50M+ immunology pact (November 2025), and the Parabilis Helicon platform (Regeneron $2.3B collaboration, June 10 $670M record IPO).
A research team published in Frontiers in Pharmacology in June 2026 a machine-learning pipeline for discovering antimicrobial peptides active against Pseudomonas aeruginosa, one of the WHO's top-priority gram-negative pathogens for new antibiotic development. The model was externally validated using 124 experimentally confirmed AMPs from recent publications. Pseudomonas aeruginosa is a leading cause of ventilator-associated pneumonia and bloodstream infection in immunocompromised patients, and the rise of carbapenem-resistant strains has narrowed remaining treatment options to colistin and ceftolozane-tazobactam. The paper sits in a broader 2026 ML-AMP wave that also includes 'Advances in the Application of Deep Learning for Antimicrobial Peptide Screening' (Agricultural Science and Food Processing) and an arxiv preprint on multilabel AMP classification benchmarks. AMP discovery is one of the few peptide-drug verticals advancing in parallel to GLP-1 headlines, with no commercial obesity-driven distortion of academic publication pipelines.
The American Gastroenterological Association published a commentary in its journal Gastroenterology on June 19, 2026 revisiting and updating the influential POWER (Practice Guide on Obesity and Weight Management, Education, and Resources) framework, originally introduced in 2017. The revised framework reflects developments since 2017: the arrival of highly effective GLP-1 weight-loss medications (semaglutide, tirzepatide, retatrutide), expanded endoscopic therapies (Fractyl Revita duodenal mucosal resurfacing, intragastric balloons, endoscopic sleeve gastroplasty), and broader use of bariatric surgery. The framework formalizes a multidisciplinary care model that treats medications, endoscopic procedures, and surgery as complementary rather than competing — and addresses the post-GLP-1 weight-regain question by positioning endoscopic 'gut reset' procedures as part of the standard treatment arsenal. The commentary frames the next era of obesity care as combining GLP-1 medications with personalized procedures and surgery for greater results.
The Journal of Nutrition published online on June 20, 2026 a review titled 'Avoiding malnutrition in the era of GLP-1 medications: emerging evidence and opportunities for integrated nutrition care.' The review documents that approximately 25% of total weight lost on GLP-1 therapy is lean mass — a substantial proportion depending on the magnitude of weight reduction achieved — and frames disproportionate fat-free mass loss as a metabolic-health and physical-function risk independent of total weight loss. The authors call for GLP-1-specific randomized trials defining optimal protein intake stratified by age, rate of weight loss, and baseline sarcopenia risk; guidance on when supplementation may be necessary; strategies for monitoring micronutrient status; and routine incorporation of body composition assessments (DXA/BIA) and standardized muscle function measures (handgrip strength, chair-rise testing) as co-primary or key secondary endpoints in future GLP-1 RA studies.
The Conference on Retroviruses and Opportunistic Infections (CROI 2026, March 9-12) featured an oral plenary by Dr. Todd Brown of Johns Hopkins Medicine titled 'GLP-1 Agonists: Are They a Cure for Everything?' alongside one oral abstract and seven posters on the use of GLP-1 receptor agonists in people living with HIV (PLWH). The findings: GLP-1s generally work well in PLWH, may improve liver fibrosis, gut tissue immune health, and cardiovascular risk, and may reduce smoking on top of the established weight loss and diabetes effects. One oral abstract suggested potential to reverse the gut damage that persists from very early HIV infection despite effective ART. Brown's plenary concluded the enthusiasm is warranted but flagged unanswered questions around long-term use and global access — particularly relevant for PLWH in low- and middle-income countries.
Pep2Tango Therapeutics presented preclinical data on PTT-A, a novel long-acting unimolecular peptide tetra-agonist activating the GLP-1, GIP, amylin, and calcitonin receptors simultaneously, in a Medscape 'Moving Beyond GLP-1s' feature drawing from the ADA 2026 session 'Novel Strategies for Obesity Pharmacology' (oral abstracts 85-OR and 299-OR, Diabetes journal supplement). In 21-day chronic studies in diet-induced obese rats, the higher PTT-A dose achieved 19% body weight reduction versus the vehicle, compared to 12% each for tirzepatide and cagrilintide + semaglutide (CagriSema). Body composition analysis showed fat-mass loss without lean-mass loss, distinguishing PTT-A's profile from tirzepatide's documented muscle-loss pattern. PTT-A also showed robust glucose lowering, plasma lipid improvement, insulin sensitization, and liver-fat benefits.
An analysis of 60,000+ Americans with type 2 diabetes, presented at ENDO 2026 by Sainikhil Sontha (Boston University School of Public Health) and published in the Endocrine Society press release stream, found that 40% of GLP-1 users discontinued the medication within 12 months and roughly 60% had stopped by the end of two years. Among those who stopped, 41.5% restarted within a year and 58% within two years. Discontinuation was higher among Medicaid/Medicare beneficiaries, Black patients, and patients with documented nausea or GI side effects (37% of stoppers). Newer-generation tirzepatide users were 41% less likely to discontinue than liraglutide users, and patients whose first GLP-1 was prescribed by an endocrinologist were 10% less likely to stop. The data complement the Cleveland Clinic 8,000-patient real-world finding (March) and the eClinicalMedicine Budini meta-regression on weight-regain trajectory, sharpening the picture of how GLP-1 therapy churn actually unfolds in US insurance-claims populations.
Frontiers in Pharmacology published June 18 a review on enhancing diabetes treatment through targeted nucleic acid and drug delivery using cell-penetrating peptides (CPPs), peptide nucleic acids (PNAs), and receptor targeting. The paper maps how CPPs can shuttle therapeutic cargo across cellular membranes in pancreatic-beta-cell and insulin-resistance contexts and how PNAs can modulate gene expression in diabetic targets, addressing the persistent delivery problem that limits peptide and oligonucleotide therapy. The review framing intersects with the broader push toward oral peptide delivery (Entera Bio EB613, Foundayo) and platform-driven peptide-conjugate therapeutics (Bicycle, Parabilis Medicines, MultiValent Biotherapeutics) reshaping the obesity, diabetes, and oncology spaces in 2026.
The American College of Cardiology, American Heart Association, American Diabetes Association, and American Society of Nephrology jointly published the first-ever clinical guideline for Cardiovascular-Kidney-Metabolic (CKM) Syndrome on June 9, 2026, in Circulation and JACC. The framework establishes a standardized CKM staging system (stages 0 to 4) to identify patients earlier, personalize therapy by absolute cardiovascular risk, and promote both prevention and regression of disease. GLP-1 receptor agonists are explicitly recommended in select patients with type 2 diabetes or obesity plus other cardiovascular risk factors, alongside SGLT2 inhibitors and kidney-protective therapies. The guideline embeds the GLP-1 class into multi-society standard of care for the first time and adds clinical-society weight to the SELECT, FLOW, and ESSENCE outcomes evidence base.
Researchers at UC San Diego and partner institutions published in Nature Communications on May 19, 2026 the first randomized, placebo-controlled clinical-trial evidence that semaglutide slows multiple validated epigenetic biomarkers of biological aging. The 32-week double-blind Phase 2b trial randomized 84 adults with HIV-associated lipohypertrophy (semaglutide n=45, placebo n=39). Semaglutide decreased PCGrimAge by 3.1 years (p=0.007), GrimAge V1 by 1.4 years (p=0.02), GrimAge V2 by 2.3 years (p=0.009), PhenoAge by 4.9 years (p=0.004), and slowed DunedinPACE by approximately 9% (-0.09 units, p=0.01). The companion SLIM LIVER study (npj Aging, same day) replicated the directional pattern. The data anchors the case for GLP-1 receptor agonists as candidate health-span extenders beyond their established cardiometabolic effects.
A target trial emulation of more than 160,000 patients, published online June 7, 2026 in Annals of Oncology and presented at ASCO 2026, reported that adults with obesity but without diabetes who received GLP-1 receptor agonists had a 41% lower risk of obesity-associated cancers compared with non-users. Subgroup signals included a 68% reduction in men and a 58% reduction in endometrial cancer. Lead author Arthur Heng-Cheng Hsu (Houston Methodist Neal Cancer Center) and colleagues examined 13 obesity-associated cancers across the TriNetX nationwide database. The findings extend prior signals from the SELECT trial (cardiovascular benefit) and FLOW (kidney benefit) into oncology and add empirical weight behind the 21-expert global panel proposal for a 10-year prospective GLP-1 cancer-prevention trial first surfaced at ECO 2026 in Istanbul.
A real-world comparison of tirzepatide and semaglutide for obesity by Venkatakrishnan and colleagues, published in PNAS Nexus on June 16, reported mean body-weight reductions of 14.7% on tirzepatide versus 10.8% on semaglutide at one year. The tirzepatide arm produced close to twice the proportion of 'high responders' (more than 15% body-weight loss) and lower rates of GI events, headache, and fatigue. Female and white patients responded more strongly on either drug than male, black, or Hispanic patients, who were more frequently in the under-5% weight-loss tier. The findings track with SURMOUNT-5's head-to-head trial result and the April 13 OMA Truveta poster but add a new demographic-disparity dimension that should inform real-world treatment selection.
A JAMA Viewpoint published June 15 by researchers from the University of Queensland, the University of Toronto, and the University of California, San Francisco flagged a fast-growing but poorly characterized trend: social-media-promoted injectable peptides for muscle growth, recovery, anti-aging, and cognition. The piece notes 130,000-plus Instagram posts and over 230 million TikTok views as of May 2026, plus a 6x rise in worldwide Google searches for 'peptides' between 2024 (1.3M/month) and 2026 (~8M/month). Substances cited include BPC-157, TB-500, and CJC-1295. The authors call for accelerated safety research and clearer regulation; the piece lands six weeks before the July 23-24 PCAC meeting that will weigh seven of those same substances for 503A compounding status.
A Stanford-led retrospective pre-post cohort study presented June 13 at ENDO 2026 in Chicago used NIH All of Us Research Program data linking electronic health records with Fitbit activity in 1,950 adults with obesity who started GLP-1 medications. Among the 753 with sufficient wearable data, mean daily steps dropped from 5,047 before GLP-1 initiation to 4,487 after (-560 steps, p<0.001); moderate-to-vigorous activity fell from 27.9 to 22.2 minutes per day (-5.7 minutes, p<0.001). The largest declines occurred in men and in people with pre-existing joint or muscle pain; age, heart failure, and stroke history did not change the pattern. Lead author Surya Maharjan flagged the activity drop as a concern given GLP-1-associated lean-mass loss.
Stanford University researchers presented retrospective cohort data at ENDO 2026 on June 13 from the Atropos Health Eos electronic health record dataset (~161 million patients seen in US community hospitals and academic medical centers, January 2016 to December 2023). Among adults with type 2 diabetes and no prior fractures or osteoporosis medication use, semaglutide was associated with a 15% lower fracture risk and greater weight loss versus other anti-obesity medications. Principal investigator Jairo Noreña framed the work as an early signal that semaglutide-driven weight loss may protect bone health in T2D, with prospective studies needed to confirm.
A research team from University Hospitals Coventry and Warwickshire and Warwick Medical School presented meta-analysis data from randomized controlled trials at ENDO 2026 on June 14 showing that 24 weeks of GLP-1 receptor agonist treatment improved testosterone levels, sperm count, and sperm morphology in men ages 18 to 65 with obesity-related low testosterone. Principal investigator Pratibha Natesh proposed reduced inflammation and metabolic stress as candidate mechanisms, with the GLP-1 class potentially preferable to testosterone replacement therapy in this population because TRT can suppress endogenous sperm production. The findings were drawn from men with high BMI, so external validity to normal-weight populations is unclear.
AJMC reported real-world claims data showing that 51.3% of patients on GLP-1 drugs carry at least one diagnosis tied to an emerging GLP-1 indication, 13.8% carry two, and 6.8% carry three or more. Obstructive sleep apnea led the comorbidity prevalence at 25.5%, followed by major depressive disorder at 18.2%, chronic kidney disease at 10.6%, and NAFLD/NASH at 10.3%. The numbers quantify the indication creep the field has been narrating since ADA: prescribers are increasingly writing GLP-1s for patients whose secondary conditions align with the expanding regulatory map (Wegovy CV, FLOW kidney, SURMOUNT-OSA, ESSENCE MASH).
Nature published a long-read on June 8 reviewing the consumer peptide boom against the actual evidence base. Worldwide Google searches for 'peptides' rose from about 1.3 million per month in 2024 to around 8 million in 2026, fueled by social media. Most popularly promoted compounds (BPC-157, TB-500, GHK-Cu, CJC-1295) rest on animal data, with one human study described as showing 'significant methodological problems and no control group.' The piece lands two months before the July 23-24 PCAC meeting that will rule on whether seven of these peptides can return to legal 503A compounding.